Incyte will share updated clinical single-cell data characterizing its calreticulin-targeted therapy for myeloproliferative ...
Advances in precision oncology have transformed cancer treatment, offering life-saving therapies to patients with limited options. However, the development of personalized medicine introduces ...
CellCarta and Imagene AI today announced an expanded collaboration to provide a coordinated path for biopharma companies to validate, deploy, and scale AI-powered biomarker and companion diagnostic ...
CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development
CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with ...
In the dynamic world of life sciences, digital pathology stands out as a beacon of innovation, promising transformative changes in how pathologists engage, evaluate, and collaborate. In this episode, ...
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for ...
Illumina, Inc. ILMN is set to partner with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight Oncology (“TSO”) Comprehensive genomic profiling test.
CellCarta and Imagene AI announced an expanded collaboration on October 1, 2026, to provide biopharma companies a coordinated ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a ...
Editor's note: This article was updated with quotes from EMA's Antonella Baron. PITTSBURGH — Ambitions for precision medicine may be lofty, but behind the scenes are some tough challenges for ...
CellCarta announced a strategic partnership with Waters Corporation, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results